[P68] ポスターセッション 68　臨床試験推進プログラム

[P68-8] LEAP-015: A Randomized Phase 3 Study of Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer

^○設樂 紘平¹, Cohen Deirdre Jill², Van Cutsem Eric³, Janjigian Yelena Y.⁴, Bang Yung-Jue⁵, Qin Shukui⁶, Wainberg Zev A.⁷, Wang Anran⁸, Hawk Natalyn Nicole⁹, Shih Chie-Schin⁸, Bhagia Pooja⁸, Tabernero Josep¹⁰ (1.国立がん研究センター東病院, 2.Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3.University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium, 4.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5.Seoul National University College of Medicine, Seoul, South Korea, 6.PLA Cancer Centre of Nanjing, Jinling Hospital, Nanjing, China, 7.Department of Medicine and Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 8.Merck & Co., Inc., Kenilworth, NJ, USA, 9.Eisai Inc., Woodcliff Lake, NJ, USA, 10.Vall d’Hebron Hospital Campus and Institute of Oncology, Barcelona, Spain)